

Supportive Care in Cancer

Longitudinal Change of Quality of Life from Pre- to 3 Months after Surgical Treatment in Head and Neck Cancer Patients --Manuscript Draft--

Manuscript Number:	
Full Title:	Longitudinal Change of Quality of Life from Pre- to 3 Months after Surgical Treatment in Head and Neck Cancer Patients
Article Type:	Original Article
Corresponding Author:	Yoshiaki Ihara, Ph.D Showa Univeristy Ohta-ku, Tokyo JAPAN
Corresponding Author Secondary Information:	
Corresponding Author's Institution:	Showa Univeristy
Corresponding Author's Secondary Institution:	
First Author:	Yuichi Tashimo, DDS.
First Author Secondary Information:	
Order of Authors:	Yuichi Tashimo, DDS. Yoshiaki Ihara, DDS., Ph.D. Ken Yuasa, DDS., Ph.D. Shinji Nozue, DDS., Ph.D. Yoshiro Saito, DDS., Ph.D. Hideyuki Katsuta, DDS., Ph.D. Toshikazu Shimane, MD., Ph.D. Koji Takahashi, DDS., Ph.D.
Order of Authors Secondary Information:	
Funding Information:	
Abstract:	<p>Purpose: Head and neck cancer (HNC) patients experience various posttreatment side effects that decrease quality of life (QOL). However, longitudinal changes of QOL in HNC patients remains unclear. This study aimed to investigate the longitudinal change of QOL in HNC patients had surgery.</p> <p>Methods: 45 HNC patients (23 men) who were scheduled for surgical treatment were enrolled in this study. Primary tumor sites were 22 tongue, 5 maxilla, 4 mandible, 3 pharynx and others. Weight, body mass index (BMI), whole body soft lean mass (SLM), and skeletal muscle mass (SMM) were evaluated as muscle mass-related measurements. Lip closure force (LC) and tongue pressure (TP) were evaluated as oral function measurements. Feeding function was evaluated using the Functional Oral Intake Scale (FOIS). QOL was assessed using the European Organization for Research and Treatment of Cancer QOL Questionnaire QLQ-C30 and H&N 35. Measures were evaluated at pre-surgical treatment (PT), and 1 month (1M) and 3 months (3M) after surgery. The change of QOL parameters and relationships between measurements were assessed.</p> <p>Results: For QOL assessments, role functioning, fatigue, speech problems, trouble with social eating, trouble with social contact, and opening mouth significantly decreased from PT to 1M, but significantly increased from 1M to 3M. Weight, BMI, SLM, SMM, LC, TP, and FOIS demonstrated significant relationships with QOL from PT to 1M. Meanwhile, from 1M to 3M, weight, BMI, SLM, SMM, LC, and FOIS showed significant relationships with QOL assessments.</p> <p>Conclusions: Both oral function and muscle mass-related measurements significantly</p>

	affected QOL in HNC patients.
Suggested Reviewers:	Michael E Groher University of Redlands Michael_Groher@redlands.edu

[Click here to view linked References](#)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Title: Longitudinal Change of Quality of Life from Pre- to 3 Months after Surgical Treatment in Head and Neck Cancer Patients

Yuichi Tashimo¹, Yoshiaki Ihara¹, Ken Yuasa¹, Shinji Nozue¹, Yoshiro Saito², Hideyuki Katsuta², Toshikazu Shimane², Koji Takahashi¹

¹Division of Oral Rehabilitation Medicine, Department of Special Needs Dentistry, Showa University School of Dentistry, Tokyo, Japan

²Head and Neck Oncology Center, Showa University Hospital, Tokyo, Japan

ORCID of the authors: 0000-0001-7961-2445 (Yuichi Tashimo)

Corresponding author:

Yoshiaki Ihara, PhD

Division of Oral Rehabilitation Medicine, Department of Special Needs Dentistry

Showa University School of Dentistry, Tokyo, Japan

Phone number: +81-33787-1151

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

e-mail address: ikkun@dent.showa-u.ac.jp

ORCID: 0000-0002-4324-2670

1
2
3
4 **Abstract**
5
6

7 Purpose: Head and neck cancer (HNC) patients experience various posttreatment side effects that
8 decrease quality of life (QOL). However, longitudinal changes of QOL in HNC patients remains unclear.
9

10
11
12 This study aimed to investigate the longitudinal change of QOL in HNC patients had surgery.
13

14
15
16 Methods: 45 HNC patients (23 men) who were scheduled for surgical treatment were enrolled in this
17
18 study. Primary tumor sites were 22 tongue, 5 maxilla, 4 mandible, 3 pharynx and others. Weight, body
19
20 mass index (BMI), whole body soft lean mass (SLM), and skeletal muscle mass (SMM) were evaluated
21
22 as muscle mass-related measurements. Lip closure force (LC) and tongue pressure (TP) were evaluated as
23
24 oral function measurements. Feeding function was evaluated using the Functional Oral Intake Scale
25
26 (FOIS). QOL was assessed using the European Organization for Research and Treatment of Cancer QOL
27
28 Questionnaire QLQ-C30 and H&N 35. Measures were evaluated at pre-surgical treatment (PT), and 1
29
30 month (1M) and 3 months (3M) after surgery. The change of QOL parameters and relationships between
31
32 measurements were assessed.
33
34
35
36
37
38
39
40

41
42 Results: For QOL assessments, role functioning, fatigue, speech problems, trouble with social eating,
43
44 trouble with social contact, and opening mouth significantly decreased from PT to 1M, but significantly
45
46 increased from 1M to 3M. Weight, BMI, SLM, SMM, LC, TP, and FOIS demonstrated significant
47
48 relationships with QOL from PT to 1M. Meanwhile, from 1M to 3M, weight, BMI, SLM, SMM, LC, and
49
50 FOIS showed significant relationships with QOL assessments.
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Conclusions: Both oral function and muscle mass-related measurements significantly affected QOL in HNC patients.

Key words: Quality of life, Muscle mass, Oral function, Feeding function, Head and neck cancer

1
2
3
4 **Introduction**
5
6
7

8 Currently, both the prevalence and survival rates of head and neck cancer (HNC) are increasing
9
10
11
12 [1] owing to advances in medical technology [2, 3]. HNC markedly affects not only oral function, but also
13
14
15
16 the cosmetic and psychological aspects [4, 5]. The acute side effects of treatment may persist beyond
17
18
19
20
21 treatment, while additional chronic effects may develop after at least 90 days after treatment discontinuation
22
23
24
25 [6, 7]. Common oral morbidities resulting from HNC treatment include oral pain, oral dryness, and altered
26
27
28
29 taste and smell perception. One of the most prevalent and debilitating side effects of HNC treatment is
30
31
32
33
34 dysphagia (i.e., swallowing difficulty) [8] that may develop as both acute and chronic complication of HNC
35
36
37
38 treatment [9, 10]. Dysphagia has been reported in over 76% of HNC patients treated with concurrent
39
40
41
42
43 chemotherapy (CRT). It decreases the patient's quality of life (QOL) following HNC treatment [11, 12].
44
45
46
47 QOL is considered to be an important factor in both treatment decision and outcome evaluation [12-15].
48
49
50
51
52 Particularly, QOL is necessary in multidirectional analysis and appropriate evaluation of treatment results.
53
54
55

56 The result of HNC treatment should be evaluated according to both QOL and posttreatment
57
58
59
60
61
62
63
64
65

1
2
3
4 functional outcomes [16]. However, only few studies have conducted a multidirectional analysis that
5
6
7
8 include QOL before and after HNC treatment. Further, majority of previous studies focused on HNC
9
10
11
12 patients who received chemoradiation therapy [3,4,8-11] and thus the association between QOL and other
13
14
15
16
17 functions in HNC patients who underwent surgery remains unclear.
18
19

20
21 This study aimed to investigate the longitudinal change of QOL in HNC patients who
22
23 underwent surgery by conducting a multidirectional analysis of pre- and posttreatment QOL.
24
25

26 27 **Materials and Methods**

28 29 30 31 *Patients*

32
33
34
35
36 This study included HNC patients who were scheduled for surgical treatment at the Head and
37
38
39
40 Neck Oncology Center, Showa University Hospital and were then referred to the Department of Special
41
42
43
44 Needs Dentistry, Division of Oral Rehabilitation Medicine, Showa University Dental Hospital for
45
46
47
48 rehabilitation. The exclusion criteria were (1) age < 20 years, (2) inability to follow instructions, (3) other
49
50
51
52
53 malignant tumors, (4) severe systemic diseases that may influence the evaluation, and (5) incomplete
54
55
56
57 measurement data.
58
59
60
61
62
63
64
65

1
2
3
4 *Assessments*
5
6
7

8 All measurements were performed by dentists of the Department of Special Needs Dentistry,
9
10
11
12 Division of Oral Rehabilitation Medicine, Showa University Dental Hospital. The primary tumor site, TNM
13
14
15
16
17 Classification, method of surgical operation, and medical history were collected from the medical records.
18
19
20
21 The patient's weight, body mass index (BMI), whole body soft lean mass (SLM), and skeletal muscle mass
22
23
24
25 (SMM) were evaluated as muscle mass-related measurements. Lip closure force (LC) and tongue pressure
26
27
28
29 (TP) were evaluated as oral function measurements. Feeding function was evaluated using the Functional
30
31
32
33
34 Oral Intake Scale (FOIS), while QOL was assessed using the European Organization for Research and
35
36
37
38 Treatment of Cancer (EORTC) QOL Questionnaire QLQ-C30 and QLQ-H&N 35.
39
40
41
42

43 Patients were examined at pre-surgical treatment (PT; 2 weeks to 2 days before surgery), a month after
44
45
46
47 surgery (1M), and 3 months after surgery (3M).
48
49
50

51 *Muscle mass-related measurements*
52
53
54
55

56 SLM and SMM were measured using Inbody S20 (BioSpace, Seoul, Korea), which can evaluate
57
58
59
60
61
62
63
64
65

1
2
3
4 the patient's SLM and SMM in supine position. The patients were placed in the supine position on the
5
6
7
8 examination table, with four electrodes on the first and third fingers and four points on the left and right
9
10
11
12 ankles, totaling to 8 contact-type electrodes [17]. The patient's weight was measured at each time point.
13
14
15
16 Changes in body weight and percentage of body weight from baseline (PT) to each time point were
17
18
19
20
21 calculated.

22 23 24 25 *Oral function measurements*

26
27
28
29
30 LC was measured 5 times using a lip force measuring device (Lip de Cum model LDC-110R,
31
32
33
34 Cosmo-Instruments Co, Ltd, Tokyo, Japan). The average score of the 5 measurements was then calculated
35
36
37
38 as the LC score [18,19].
39
40
41
42

43 TP was evaluated using the JMS tongue pressure measuring device (JMS Co. Ltd., Hiroshima, Japan).
44
45
46
47 The balloon-shaped intraoral probe was placed behind the upper front teeth. Patients were instructed to
48
49
50
51
52 push the probe with the maximum force between the hard palate and tongue, and changes in air pressure
53
54
55
56 inside the probe was measured. The measurement was performed 10 times, and the average score was
57
58
59
60
61
62
63
64
65

1
2
3
4 calculated as the TP score [20].
5
6

7
8 *Feeding function*
9

10
11
12 The FOIS was used as a measure of functional eating status [21]. The FOIS is a valid and reliable
13
14
15
16
17 tool used to document functional eating abilities. A 7-point ordinal scale describes the functional oral intake
18
19
20
21 of patients with dysphagia.
22
23

24
25 *QOL measurements*
26

27
28
29
30 QOL was assessed using the Japanese version of EORTC QLQ-C30 version 3.0 and QLQ-
31
32
33
34 H&N35 questionnaires. The scores were calculated according to the EORTC scoring manual [22,23].
35
36
37

38
39 *Statistical analysis*
40

41
42
43 Univariate analyses of potential associations were conducted using t-tests for the comparison of
44
45
46
47 all measurements at each time point. Spearman's rank correlation coefficient was used to evaluate the
48
49
50
51 relationships among QOL measurements that significantly decreased after HNC treatment and other
52
53
54
55
56 measurements from PT to 1M and 1M to 3M. Statistical analyses were performed using IBM SPSS version
57
58
59
60
61
62
63
64
65

1
2
3
4 25 (IBM, New York, USA). All p values were two-sided, and $p < 0.05$ was considered significant.
5
6
7

8 **Results**

9 *Patients*

10
11
12
13
14
15
16
17
18 A total of 45 patients (23 men and 22 women) were included in the study. The mean patient age
19
20
21
22 was 66.51 years (SD: 12.5 years). The primary tumor site was the tongue, maxilla, mandible, pharynx,
23
24
25
26 and others in 22, 5, 4, 3, and 11 patients, respectively. The patients' characteristics are detailed in Table 1.
27
28
29
30

31 *Muscle mass-related measurements*

32
33
34
35
36 Weight: At PT, the average weight was 60.27 kg (SD = 13.02 kg). A significant reduction was
37
38
39
40 observed at 1M (mean: 58.32 kg, SD = 11.82 kg; $t = 5.41$, $p < .001$), while no significant increase was
41
42
43
44 noted from 1M to 3M (mean: 58.10 kg, SD = 12.23 kg; $t = -0.59$, $p = .560$). In addition, the average
45
46
47
48 weight was significantly reduced from PT to 3M ($t = 3.86$, $p < .001$; Fig. 1a).
49
50
51
52

53 BMI: At PT, the average BMI was 23.02 kg/m² (SD = 3.52 kg/m²). A significant reduction was
54
55
56
57 observed at 1M (mean: 22.20 kg/m², SD = 3.41 kg/m²; $t = 5.75$, $p < .001$). However, the average BMI was
58
59
60
61
62
63
64
65

1
2
3
4 not significantly increased at 3M (mean: 22.40 kg/m², SD = 3.40 kg/m²) than that at 1M (t = 0.29, p
5
6
7
8 = .770). Furthermore, the average BMI at 3M was significantly reduced from that at PT (t = 3.95, p
9
10
11
12
13 < .001; Fig. 1b).

14
15
16
17 SLM: At PT, the average SLM was 38.32 kg (SD = 9.52 kg). A significant reduction was
18
19
20
21 observed at 1M (mean: 38.00 kg, SD = 8.81 kg; t = 2.10, p = .040). Meanwhile, no significant change in
22
23
24
25 the average SLM was observed at 3M compared to that at 1M (mean: 38.00 kg, SD = 9.22 kg; t = 1.57, p
26
27
28
29 = .125). Furthermore, the average SLM at 3M showed no significant changes (t = 1.30, p = .200)
30
31
32
33
34 compared to that at PT (Fig. 1c).

35
36
37
38
39 SMM: At PT, the average SMM was 22.10 kg (SD = 5.82 kg). A significant reduction was
40
41
42
43 observed at 1M (mean: 21.72 kg, SD = 5.23 kg; t = 2.59, p = .010). Meanwhile, there was no significant
44
45
46
47 reduction in the average SMM at 3M (mean: 21.79 kg, SD = 5.57 kg; t = -1.97, p = .056) compared to that
48
49
50
51 at 1M. Furthermore, no significant change in the average SMM at 3M compared to that at PT was noted (t
52
53
54
55 = 1.66, p = .100; Fig. 1d).

1
2
3
4 *Oral function measurements*
5
6
7

8 LC: At PT, the average LC was 12.33 N (SD = 3.03 N). A significant reduction was observed at
9
10
11
12 1M (mean: 10.80 N, SD = 3.19 N; $t = 3.47$, $p = .001$). Meanwhile, the average LC showed no significant
13
14
15
16
17 change at 3M compared to that at 1M (mean: 11.79 N, SD = 3.27 N; $t = -1.73$, $p = .092$). Furthermore, the
18
19
20
21 average LC at 3M showed no significant change compared to that at PT ($t = 1.56$, $p = .127$; Fig. 2a).
22
23
24

25 TP: At PT, the average TP was 26.89 kPa (SD = 10.21 kPa). A significant reduction (was
26
27
28
29
30 observed at 1M (mean: 22.30 kPa, SD = 11.43; $t = 4.23$, $p < .001$). At 3M, the average TP was
31
32
33
34 significantly increased (mean: 25.47 kPa, SD = 12.23; $t = -3.17$, $p = .003$) compared to that at 1M.
35
36
37
38
39 Meanwhile, the average TP at 3M showed no significant change compared to that at PT ($t = 1.65$, p
40
41
42 = .107; Fig. 2b).
43
44
45
46

47 *Feeding function*
48
49
50
51

52 FOIS: At PT, the average FOIS was 6.73 (SD = 0.72). At 1M, the mean FOIS was significantly
53
54
55
56 decreased (mean: 5.89; SD = 1.49; $t = 4.07$, $p < .001$). Meanwhile, the mean FOIS score at 3M was
57
58
59
60
61
62
63
64
65

1
2
3
4 significantly increased compared to that at 1M (mean: 6.36, SD = 1.49; $t = -3.17$, $p = .003$). Furthermore,
5
6
7
8 the average FOIS at 3M was not significantly different from that at PT ($t = 1.88$, $p = .068$; Fig. 2c).
9

10 11 12 *QOL measurements*

13
14
15
16 For QOL measurements, no significant change was noted from PT to 1M in Global health
17
18
19
20
21 status ($p = .768$). However, it increased significantly from 1M to 3M ($p = .039$). For functional scales,
22
23
24
25 physical functioning (PF 2) and role functioning (RF 2) decreased significantly from PT to 1M (PF 2; p
26
27
28 = .001, RF 2; $p = .004$), while RF2, EF, and SF increased significantly from 1M to 3M (RF 2; $p = .005$,
29
30
31 EF; $p = .048$, SF; $p = .007$). Only RF2 indicated a significant change in both PT to 1M and 1M to 3M
32
33
34
35
36
37
38
39 (Fig. 3a). In symptom scales, fatigue (FA), dyspnea (DY), senses problems (HNSE), speech problems
40
41
42
43 (HNSP), trouble with social eating (HNSO), trouble with social contact (HNSC), opening mouth
44
45
46
47 (HNOM), and weight gain (HNWG) decreased significantly from PT to 1M (FA; $p = .004$, DY; $p = .011$,
48
49
50
51
52 HNSE; $p = .021$, HNSP; $p < .001$, HNSO; $p = .027$, HNSC; $p = .001$, HNOM; $p = .009$, HNWG; p
53
54
55
56 = .010). Furthermore, FA, pain (PA), insomnia (SL), appetite loss (AP), HNSW, , HNSP, HNSO,
57
58
59
60
61
62
63
64
65

1
2
3
4 HNSC, and HNOM increased significantly from 1M to 3M (FA; $p = .011$, PA; $p = .022$, SL; $p = .037$, AP;
5
6
7
8 $p = .027$, HNSW; $p = .010$, HNSP; $p = .001$, HNSO; $p = .043$, HNSC; $p < .001$, HNOM; $p = .002$). In
9
10
11
12 addition, FA, HNSP, HNSO, HNSC, and HNOM showed significant change in both PT to 1M and 1M to
13
14
15
16
17 3M (Fig. 3b).

21 *Correlation between QOL items and other measurement items*

22
23
24
25 From PT to 1M, PF2 showed significant strong correlation with weight ($r = .490$, $p = .001$),
26
27
28
29 BMI ($r = .485$, $p = .001$), TP ($r = .581$, $p < .001$), and FOIS ($r = .419$, $p = .007$). HNSP showed significant
30
31
32
33
34 strong correlation with TP ($r = -.424$, $p = .006$). HNSC also showed significant strong correlation with
35
36
37
38 weight ($r = -.512$, $p = .001$), BMI ($r = -.537$, $p < .001$), SMM ($r = -.415$, $p = .008$), TP ($r = -.615$, p
39
40
41
42 $< .001$), and FOIS ($r = -.681$, $p < .001$) (Table 2). From 1M to 3M, RF2 demonstrated significant
43
44
45
46
47 correlation with weight ($r = -0.497$, $p = .001$) and BMI ($r = -.447$, $p = .004$). Further, EF, SF, SL, and AP
48
49
50
51 demonstrated significant correlation with FOIS (EF: $r = .552$, $p < .001$; SF: $r = .517$, $p = .001$; SL: $r =$
52
53
54
55
56 $-.549$, $p = .001$; and AP: $r = -.427$, $p = .007$) (Table 3).
57
58
59
60
61
62
63
64
65

1
2
3
4 **Discussion**
5
6
7

8
9
10 In this study, we investigated the relationship between the side effects of HNC surgical
11
12 treatment and QOL. The results showed that several aspects of muscle mass related measurements and
13
14 oral function measurements, particularly feeding function, were significantly deteriorated following HNC
15
16
17
18 surgical treatment with incomplete recovery at 3 months post-treatment. Regarding QOL measurement,
19
20
21
22
23 only RF2 indicated significant decrease following HNC surgical treatment in functional scales. However,
24
25
26
27 several factors in symptom scales indicated significant decrease following treatment. All muscle mass-
28
29
30
31
32 related measurements and oral function measurements, including feeding function, indicated significant
33
34
35
36
37 relationship with QOL. Furthermore, different patterns of relationships were obtained at the 1M vs. 3M
38
39
40
41
42
43
44 time points.
45
46

47
48 The reduction of oral function might be related to the surgical region of HNC. In this study,
49
50
51
52
53 patients underwent only surgical treatment, and although oral function decreased after surgical treatment,
54
55
56
57
58 it was recovered after 3 months. Unlike external beam radiation therapy and CRT, surgical treatment has
59
60
61
62
63
64
65

1
2
3
4 less additional chronic effects on oral function [24]. However, surgical treatment has strong acute side
5
6
7
8 effects such as wound pain, and this might have influenced the result of this study. Moreover, the patients
9
10
11
12 in this study underwent oral function rehabilitation, such as tongue strength, LC, and respiratory muscle
13
14
15
16 strength training. These rehabilitations helped to improve oral function. In addition, majority of patients
17
18
19
20
21 in this study (58%) had stage I or II. These patients treated with free tissue transfer. It was reported that
22
23
24
25 single-stage reconstruction of head and neck like free tissue transfer reconstruction defected with much
26
27
28
29
30 greater success and less morbidity [25].
31

32
33
34 The QOL of HNC patients has been reported to decrease after treatment and did not recover to
35
36
37
38 baseline level [26]. In this study, the same tendency was noted in the symptom scale evaluation items. At
39
40
41
42
43 1M, the FA, DY, HNSE, HNRP, HNSO, HNSC, HNOM, and HNWG were significantly decrease from
44
45
46
47 that at PT. One possible reason might be that patients were still not fully recovered at this time point
48
49
50
51 because of anatomical changes in the pharynx and oral cavity, decrease of dexterity, limitations in range
52
53
54
55
56 of movement, and decrease in moving speed.
57
58
59
60
61
62
63
64
65

1
2
3
4 From PT to 1M, significant relationships were noted between QOL assessments and other
5
6
7
8 measurements (14 items of muscle mass related measurements, 10 items of oral function measurements,
9
10
11
12 and 5 items of feeding function). These results indicate that both muscle mass related measurements and
13
14
15
16 oral function measurements had significant effects on QOL, and these functions were not recovered from
17
18
19
20
21 at 1 month after surgical treatment. In this study, because of pain and/or healing process of wound area,
22
23
24
25 over a week was necessarily to begin rehabilitation after surgical treatment for patients who underwent
26
27
28
29 minor surgical treatment like partial glossectomy. Moreover, it is thought that a longer time was necessary
30
31
32
33
34 to begin rehabilitation after surgical treatment for patients who underwent major surgery such as
35
36
37
38 reconstructive surgery of the oral cavity. The common oral morbidities during the early stage of HNC
39
40
41
42
43 treatment include dysphagia, oral pain, and oral dryness [24]. This might have caused the significant
44
45
46
47 association between oral function and QOL. Moreover, some patients were still hospitalized at 1 month
48
49
50
51 postoperative, and others were placed on tube feeding, causing difficulty in achieving adequate nutrition.
52
53
54
55
56 In addition, some patients needed modified diets, which might have caused the significant association of
57
58
59
60
61
62
63
64
65

1
2
3
4 BMI and weight with QOL.
5
6
7

8 Meanwhile, from 1M to 3M, different relationships were noted between QOL assessments and
9
10
11
12 other measurements (5 items of muscle mass-related measurements, one item of oral function
13
14
15
16 measurements, and 8 items of feeding function). Particularly, the evaluation measurements of oral
17
18
19
20
21 function decreased to only a measurement (LC) between 1M and 3M. This indicated that a decrease in
22
23
24
25 oral function had significant effect on QOL at the early stage following treatment. However, the effect
26
27
28
29 became weak at 3 months postoperative. One possible reason might be that rehabilitation of oral function
30
31
32
33 improves oral function (TP, LC). Nevertheless, feeding function (FOIS), which involves complex
34
35
36
37
38 movement (both oral and pharyngeal), remained significantly correlated with QOL, indicating that oral
39
40
41
42 function requiring complex movements such as feeding, speech, and social contact had stronger effect on
43
44
45
46
47 QOL than simple function such as TP and LC. It was reported that social oral function, such as speech
48
49
50
51 and eating, had strong effects on QOL during the late stage after treatment [27]. Similar results were
52
53
54
55
56 obtained in this study.
57
58
59
60
61
62
63
64
65

1
2
3
4 The difference in correlation between PT - 1M and 1M - 3M is considered to be primarily due
5
6
7
8 to functional deterioration because of surgical treatment and changes in the social environment. A
9
10
11
12 previous study suggested that factors influencing QOL assessment were highly correlated with the time
13
14
15
16 period after surgery and social environment of patients after social reversion [28]. In this study, single
17
18
19
20
21 function such as LC and TP showed a significant correlation with change in QOL item at 1M. However,
22
23
24
25 only LC indicated significant correlation to QOL assessment. Meanwhile, measurement items involving
26
27
28
29
30 many factors (FOIS, SMM, and SLM) were correlated with QOL. Other QOL items correlated with other
31
32
33
34 measurements did not change at PT - 1M and 1M - 3M. As for correlation coefficients, no factors
35
36
37
38 showing strong correlation were recognized. This point might indicate that the QOL of HNC patients who
39
40
41
42 underwent surgical treatment is influenced by multiple factors, and not a single factor. This means that
43
44
45
46 improving the QOL of HNC patients requires a multifactorial approach, and strategies need to be
47
48
49
50
51 patterned according to the time posttreatment. Dysphagia is among the most prevalent and debilitating
52
53
54
55 symptoms resulting from HNC treatment. It has been reported that different mechanisms may contribute
56
57
58
59
60
61
62
63
64
65

1
2
3
4 to the development and maintenance of dysphagia during HNC treatment [8]. The pattern in correlation
5
6
7
8 between QOL and functional assessment items differed according to the time point after treatment.
9

10
11
12
13 *Limitations*
14

15
16
17
18 This prospective cohort study included a small sample owing to its single-center design and
19
20
21
22 loss to follow-up. Patient drop out during a prospective HNC study is not unusual [29,30]. In addition,
23
24
25
26 patients were only followed for 3 months posttreatment. Postoperative dysfunction persists over 1 month
27
28
29
30 and over 3-12 months after major surgery and radiation therapy, respectively [31,32]. Furthermore,
31
32
33
34
35 additional variables such as type, amount, and duration of medications (particularly pain medications)
36
37
38
39
40 might have influenced the results. Thus, to better clarify the proposed patterns reported in the current
41
42
43
44 study, future studies should incorporate larger samples, follow patients for a longer post-treatment
45
46
47
48 duration, and consider additional variables that potentially influence the observed outcomes. In this study,
49
50
51
52
53 we did not evaluate physical function such as walking speed, hand grip, and performance of activities of
54
55
56
57 daily living. The correlation between the QOL of HNC patients who underwent surgical treatment and
58
59
60
61
62
63
64
65

1
2
3
4 physical function should be investigated in future studies. In addition, it will be necessary that we
5
6
7
8 consider classification by primary site (e.g., tongue, faucial arch, and pharynx) and identify the difference
9
10
11
12 in treatment methods (surgery, radiation therapy, chemo therapy, and combined therapy).
13
14
15
16

17 *Conclusion*

18
19
20
21
22
23
24 Muscle mass-related measurements, oral function measurements, and feeding function deteriorate
25
26
27
28
29 significantly following surgical treatment for HNC and are not recovered completely at 3 months
30
31
32
33
34
35
36 posttreatment. Furthermore, the different patterns of relationships between QOL measurements and oral
37
38
39
40
41 functions or muscle mass-related measurements obtained at each assessment point indicate that different
42
43
44
45
46
47 factors influence the QOL in HNC patients who undergo surgical treatment.
48
49
50

51 **Compliance with Ethics Standards**

- 52
53
54 • The authors declare that they have no conflicts of interest.
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

- Research involving Human Participants and/or Animals: This study was approved by the Ethics Committee of Showa University School of Medicine (Approval no. 2355).
- Informed consent: Informed consent was obtained from all individual participants included in the study

1
2
3
4 **References**
5
6
7

- 8 1. Young D, Xiao CC, Murphy B et al (2015) Increase in head and neck cancer in younger patients
9
10
11
12 due to human papillomavirus (HPV). *Oral Oncol* 51(8):727–730
13
14
15
16
17 2. American Cancer Society. (2016) *Cancer fact & Figure*. Atlanta. 2016;1–10.
18
19
20
21 3. Van den Berg MG, Rütten H, Rasmussen-Conrad EL et al (2014) Nutritional status, food intake,
22
23
24
25 and dysphagia in long-term survivors with head and neck cancer treated with
26
27
28
29
30 chemoradiotherapy: a cross-sectional study. *Head Neck* 36(1):60–65
31
32
33
34 4. Rütten H, Pop LA, Janssens GO et al (2011) Long-term outcome and morbidity after treatment
35
36
37 with accelerated radiotherapy and weekly cisplatin for locally advanced head-and-neck cancer:
38
39 results of a multidisciplinary late morbidity clinic. *Int J Radiat Oncol Biol Phys* 81(4):923–929
40
41
42 5. Crary MA, Carnaby GD, Sia I (2014) Spontaneous swallow frequency compared with clinical
43
44
45 screening in the identification of dysphagia in acute stroke. *J Stroke Cerebrovasc Dis*
46
47
48 23(8):2047–2053
49
50
51 6. Ganzer H, Rothpletz-Puglia P, Byham-Gray L, Murphy BA, Touger-Decker R. (2015) The
52
53
54
55
56 eating experience in long-term survivors of head and neck cancer: a mixed-methods study.
57
58
59
60
61
62
63
64
65

1
2
3
4 Support Care Cancer 23(11):3257-68. 10.1007/s00520-015-2730-9.
5
6
7

8 7. Glastonbury CM, Parker EE, Hoang JK (2010) The postradiation neck: evaluating response to
9

10
11
12 treatment and recognizing complications. *AJR Am J Roentgenol* 195(2):W164–W171
13
14
15

16 8. Ihara Y, Crary MA, Madhavan A et al (2018) Dysphagia and Oral Morbidities in
17
18
19

20
21 Chemoradiation-Treated Head and Neck Cancer Patients. *Dysphagia* 33(6):739–748
22
23
24

25 9. Hutcheson KA, Lewin JS, Barringer DA et al (2012) Late Dysphagia after Radiotherapy-Based
26
27
28

29
30 Treatment of Head and Neck Cancer. *Cancer* 1;118(23):5793–5799
31
32
33

34 10. Van den Berg MG, Rütten H, Rasmussen-Conrad EL et al (2014) Nutritional status, food intake,
35
36
37

38
39 and dysphagia in long-term survivors with head and neck cancer treated with
40
41
42

43 chemoradiotherapy: a cross-sectional study. *Head Neck* 36 (1): 60–65
44
45
46

47 11. Kalyanam B, Sarala N, Azeem Mohiyuddin SM, Diwakar R (2018) Auditory function and
48
49
50

51
52 quality of life in patients receiving cisplatin chemotherapy in head and neck cancer: A case
53
54
55

56 series follow-up study. *J Cancer Res Ther* 14(5):1099–1104
57
58
59
60
61
62
63
64
65

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

12. Anuradha V, Anand BB, Suresh AVS, Sinha S, Chinna Babu S, Suresh K (2013) Palliative chemotherapy in head and neck squamous cell cancer - What is best in Indian population? A time without symptoms, treatment toxicity score based study. *Indian J Med Paediatr Oncol* 34(1):11–15

13. Blazeby JM, Williams MH, Brookes ST, Alderson D, Farndon JR (1995) Quality of life measurement in patients with oesophageal cancer. *Gut* 37(4):505–508

14. Maciejewski O, Smeets R, Gerhards F et al (2010) Gender-specific quality of life in patients with oral squamous cell carcinomas. *Head Face Med* 20;6:21

15. Gonçalves JJ, Álvaro M (2012) A decision support system for quality of life in head and neck oncology patients. *Head Neck Oncol* 4:3

16. Guenzel T, Walliczek-Dworschak U, Teymoortash A et al (2018) Health-related quality of life in oropharyngeal cancer survivors - a population-based study. *Otolaryngol Pol* 30;72(2):30–35

17. Okamoto M, Fukui M, Kurusu A, et al (2006) Usefulness of a body composition analyzer, InBody 2.0, in chronic hemodialysis patients. *Kaohsiung J Med Sci* 22(5):207–210

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

18. Morisaki N, Miura H, Hara S (2015) Relationship between the nutritional status and the oral function among community-dwelling dependent elderly persons. *Nihon Ronen Igakkai Zasshi* 52(3):233–242

19. Ono T, Hori K, Ikebe K, Nokubi T, Nago S, Kumakura I (2003) Factors influencing eating ability of old in-patients in a rehabilitation hospital in Japan. *Gerodontology* 20(1):24–31

20. Hasegawa Y, Sugahara K, Fukuoka T et al (2017) Change in tongue pressure in patients with head and neck cancer after surgical resection. *Odontology* 105(4):494–503

21. Crary MA, Mann GD, Groher ME (2005) Initial psychometric assessment of a functional oral intake scale for dysphagia in stroke patients. *Arch Phys Med Rehabil* 86(8):1516–1520

22. Aaronson NK, Ahmedzai S, Bergman B et al (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. *J Natl Cancer Inst* 3;85(5):365–376

23. Fayers PM, Aaronson NK, Bjordal K, Groenvold M, Curran D, Bottomley A (2001) European organisation for research and treatment of cancer care. *The EORTC QLQ C30 Scoring Manual*, 3rd edn. Brussels

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

24. Luo J, Wu J, Lv K et al (2016) Analysis of Postsurgical Health-Related Quality of Life and Quality of Voice of Patients With Laryngeal Carcinoma. *Medicine (Baltimore)* 95(1):e2363

25. Chim H, Salgado CJ, Seselgyte R, Wei FC, Mardini S (2010) Principles of Head and Neck Reconstruction: An Algorithm to Guide Flap Selection. *Semin Plast Surg* 24(2):148–154.

26. Loorents V, Rosell J, Salgado Willner H, Börjeson S (2016) Health-related quality of life up to 1 year after radiotherapy in patients with head and neck cancer (HNC). *Springerplus* 5(1):669

27. Carnaby GD, Crary MA (2014) Development and validation of a cancer-specific swallowing assessment tool: MASA-C. *Support Care Cancer* 22(3):595–602

28. List MA, Stracks J, Colangelo L et al (2000) How do head and neck cancer patients prioritize treatment outcomes before initiating treatment? *J Clin Oncol* 18(4):877–884

29. Rademaker AW, Vonesh EF, Logemann JA et al (2003) Eating ability in head and neck cancer patients after treatment with chemoradiation: A 12-months follow-up study accounting for dropout. *Head Neck* 25(12):1034–1041

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

30. Shinn EH, Basen-Engquist K, Baum G et al (2013) Adherence to Preventive Exercises and Self-Reported Swallowing Outcomes in Post-Radiation Head and Neck Cancer Patients. *Head Neck* 35(12):1707–1712

31. Chandu A, Smith ACH, Rogers SN (2006) Health-related quality of life in oral cancer: a review. *J Oral Maxillofac Surg* 64:495–502

32. Murphy BA, Ridner SR, Wells N, Dietrich M (2007) Quality of life research in head and neck cancer: a review of the current state of the science. *Crit Rev Oncol Hematol* 62:251–267

Figure Legends

Fig. 1 Muscle mass related measurement outcomes

a: Change in weight; b: Change in BMI; c: Change in SLM; d: Change in SMM

Fig. 2 Oral function measurements and feeding outcomes

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

a: Change in LC; b: Change in TP; c: Change in FOIS

Fig. 3 QOL measurement outcomes

a: Significant change in functional scale; b: Significant change in symptom scales

Variables	N=45
Gender (Male : Female)	(23: 22)
Age (mean, SD, range)	66.51, 12.50, 36-85
Tumour site	
Tongue	22
Maxilla	5
Mandible	4
Pharynx	3
Thyroid	6
Oropharynx	2
hypopharynx	2
Salivary gland	1
Tumour size	
T	
is	2
1	15
2	13
3	7
4a	5
4b	3
N	
0	34
+	11
Tumour stage	
0	2
I	12
II	12
III	9
IVA	8
IVB	2


Table 1. Patient characteristics (N=45)




QOL items	Measurement items	correlation coefficients	P value
PF2	Weight	.490	.001
	BMI	.485	.001
	LC	.369	.019
	TP	.581	<.001
	FOIS	.419	.007
RF2	TP	.320	.044
	FOIS	.386	.014
FA	TP	-.330	.038
HNSE	BMI	-.308	.050
	TP	-.327	.039
HNSP	SLM	-.344	.030
	SMM	-.344	.030
	LC	-.324	.042
	TP	-.424	.006
	FOIS	-.366	.020
HNSO	SLM	-.382	.018
	SMM	-.354	.029
	FOIS	-.376	.020
HNSC	Weight	-.512	.001
	BMI	-.537	<.001
	SLM	-.385	.014
	SMM	-.415	.008
	LC	-.365	.021
	TP	-.615	<.001
	FOIS	-.681	<.001
HNOM	Weight	-.330	.035
	SLM	-.369	.019
	SMM	-.375	.017
	TP	-.342	.031


Table 2. Correlation between QOL Items and other measurement items from PT to 1M

QOL items	Measurement items	correlation coefficients	P value
RF2	Weight BMI	-.517	.001
		-.436	.005
EF	FOIS	.450	.004
SF	FOIS	.445	.005
FA	FOIS	-.339	.035
PA	FOIS	-.340	.034
SL	LC FOIS	-.328	.048
		-.549	.001
AP	FOIS	-.427	.007
HNSW	FOIS	-.351	.033
HNSP	SLM	-.323	.039
HNSO	SLM SMM	-.342	.031
		-.332	.036
HNSC	FOIS	-.341	.034

Table 3. Correlation between QOL items and other measurement items from 1M to 3M.



a**b****c**



Please wait...

If this message is not eventually replaced by the proper contents of the document, your PDF viewer may not be able to display this type of document.

You can upgrade to the latest version of Adobe Reader for Windows®, Mac, or Linux® by visiting http://www.adobe.com/go/reader_download.

For more assistance with Adobe Reader visit <http://www.adobe.com/go/acrreader>.

Windows is either a registered trademark or a trademark of Microsoft Corporation in the United States and/or other countries. Mac is a trademark of Apple Inc., registered in the United States and other countries. Linux is the registered trademark of Linus Torvalds in the U.S. and other countries.

Please wait...

If this message is not eventually replaced by the proper contents of the document, your PDF viewer may not be able to display this type of document.

You can upgrade to the latest version of Adobe Reader for Windows®, Mac, or Linux® by visiting http://www.adobe.com/go/reader_download.

For more assistance with Adobe Reader visit <http://www.adobe.com/go/acrreader>.

Windows is either a registered trademark or a trademark of Microsoft Corporation in the United States and/or other countries. Mac is a trademark of Apple Inc., registered in the United States and other countries. Linux is the registered trademark of Linus Torvalds in the U.S. and other countries.

Please wait...

If this message is not eventually replaced by the proper contents of the document, your PDF viewer may not be able to display this type of document.

You can upgrade to the latest version of Adobe Reader for Windows®, Mac, or Linux® by visiting http://www.adobe.com/go/reader_download.

For more assistance with Adobe Reader visit <http://www.adobe.com/go/acrreader>.

Windows is either a registered trademark or a trademark of Microsoft Corporation in the United States and/or other countries. Mac is a trademark of Apple Inc., registered in the United States and other countries. Linux is the registered trademark of Linus Torvalds in the U.S. and other countries.

Please wait...

If this message is not eventually replaced by the proper contents of the document, your PDF viewer may not be able to display this type of document.

You can upgrade to the latest version of Adobe Reader for Windows®, Mac, or Linux® by visiting http://www.adobe.com/go/reader_download.

For more assistance with Adobe Reader visit <http://www.adobe.com/go/acrreader>.

Windows is either a registered trademark or a trademark of Microsoft Corporation in the United States and/or other countries. Mac is a trademark of Apple Inc., registered in the United States and other countries. Linux is the registered trademark of Linus Torvalds in the U.S. and other countries.

Please wait...

If this message is not eventually replaced by the proper contents of the document, your PDF viewer may not be able to display this type of document.

You can upgrade to the latest version of Adobe Reader for Windows®, Mac, or Linux® by visiting http://www.adobe.com/go/reader_download.

For more assistance with Adobe Reader visit <http://www.adobe.com/go/acrreader>.

Windows is either a registered trademark or a trademark of Microsoft Corporation in the United States and/or other countries. Mac is a trademark of Apple Inc., registered in the United States and other countries. Linux is the registered trademark of Linus Torvalds in the U.S. and other countries.

Please wait...

If this message is not eventually replaced by the proper contents of the document, your PDF viewer may not be able to display this type of document.

You can upgrade to the latest version of Adobe Reader for Windows®, Mac, or Linux® by visiting http://www.adobe.com/go/reader_download.

For more assistance with Adobe Reader visit <http://www.adobe.com/go/acrreader>.

Windows is either a registered trademark or a trademark of Microsoft Corporation in the United States and/or other countries. Mac is a trademark of Apple Inc., registered in the United States and other countries. Linux is the registered trademark of Linus Torvalds in the U.S. and other countries.

Please wait...

If this message is not eventually replaced by the proper contents of the document, your PDF viewer may not be able to display this type of document.

You can upgrade to the latest version of Adobe Reader for Windows®, Mac, or Linux® by visiting http://www.adobe.com/go/reader_download.

For more assistance with Adobe Reader visit <http://www.adobe.com/go/acrreader>.

Windows is either a registered trademark or a trademark of Microsoft Corporation in the United States and/or other countries. Mac is a trademark of Apple Inc., registered in the United States and other countries. Linux is the registered trademark of Linus Torvalds in the U.S. and other countries.

Please wait...

If this message is not eventually replaced by the proper contents of the document, your PDF viewer may not be able to display this type of document.

You can upgrade to the latest version of Adobe Reader for Windows®, Mac, or Linux® by visiting http://www.adobe.com/go/reader_download.

For more assistance with Adobe Reader visit <http://www.adobe.com/go/acrreader>.

Windows is either a registered trademark or a trademark of Microsoft Corporation in the United States and/or other countries. Mac is a trademark of Apple Inc., registered in the United States and other countries. Linux is the registered trademark of Linus Torvalds in the U.S. and other countries.